Takeda Pharmaceutical (TAK) Non Operating Income (2019 - 2020)

Takeda Pharmaceutical (TAK) posted Non Operating Income of -$938.9 million for Q3 2020, down 173.35% on a QoQ basis from -$343.5 million in Q1 2020.

Analysis

Takeda Pharmaceutical (TAK) Non Operating Income (2019 - 2020) Analysis & Trends

Takeda Pharmaceutical has reported Non Operating Income for 2 years, with the latest figure at -$938.9 million in Q3 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Johnson & Johnson	645.47 Bn	624.71 Bn	17.26 Bn	-
2	AbbVie	439.99 Bn	433.42 Bn	12.70 Bn	-
3	Merck	365.45 Bn	358.31 Bn	12.21 Bn	-
4	Novartis Ag	266.57 Bn	258.88 Bn	11.24 Bn	-
5	Pfizer	159.03 Bn	147.33 Bn	10.94 Bn	-
6	Sanofi	52.43 Bn	45.05 Bn	10.79 Bn	-
7	Revolution Medicines	44.23 Bn	44.23 Bn	-	-139.24 Mn
8	Incyte	25.32 Bn	20.79 Bn	1.57 Bn	-
9	United Therapeutics	21.44 Bn	18.77 Bn	683.80 Mn	41.90 Mn
10	Takeda Pharmaceutical	2.61 Bn	-3.19 Bn	5.10 Bn	-

Historic Data

Download Data